Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott C Morgan

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
Oncology Nursing Forum|June 20, 2020
Comparing Interventions for Management of Hot Flashes in Patients With Breast and Prostate Cancer: A Systematic Review With Meta-AnalysesBrian Hutton, Mona Hersi, Wei Cheng, et al.
JCO Oncology Practice|January 13, 2026
Association Between Sociodemographic Marginalization and Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer: Population-Based Cohort Study in Ontario, CanadaDavid-Dan Nguyen, Raj Satkunasivam, Khatereh Aminoltejari, et al.
European Urology|March 9, 2023
Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 TrialSoumyajit Roy, Yilun Sun, Scott C Morgan, et al.
Practical Radiation Oncology|October 17, 2018
Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based GuidelineScott C Morgan, Karen Hoffman, D Andrew Loblaw, et al.
The Journal of Urology|February 15, 2019
Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based GuidelineScott C Morgan, Karen Hoffman, D Andrew Loblaw, et al.
Cancer|September 4, 2025
Association of patient and physician characteristics with androgen-deprivation-therapy intensification in patients with de novo hormone-sensitive metastatic prostate cancer: A population-based studyDavid-Dan Nguyen, Raj Satkunasivam, Khatereh Aminoltejari, et al.
JAMA Network Open|October 15, 2024
Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical TrialSoumyajit Roy, Shawn Malone, Kevin Wing, et al.
The Journal of Urology|July 26, 2024
Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of the TITAN TrialSoumyajit Roy, Yilun Sun, Kim N Chi, et al.
JNCI Cancer Spectrum|December 20, 2021
Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate CancerChristopher J D Wallis, Shawn Malone, Ilias Cagiannos, et al.
Cancers|July 2, 2021
Prognostic Association between Common Laboratory Tests and Overall Survival in Elderly Men with De Novo Metastatic Castration Sensitive Prostate Cancer: A Population-Based Study in CanadaChristopher J D Wallis, Bobby Shayegan, Scott C Morgan, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Oncology Nursing Forum|June 20, 2020
Comparing Interventions for Management of Hot Flashes in Patients With Breast and Prostate Cancer: A Systematic Review With Meta-AnalysesBrian Hutton, Mona Hersi, Wei Cheng, et al.
JCO Oncology Practice|January 13, 2026
Association Between Sociodemographic Marginalization and Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer: Population-Based Cohort Study in Ontario, CanadaDavid-Dan Nguyen, Raj Satkunasivam, Khatereh Aminoltejari, et al.
European Urology|March 9, 2023
Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 TrialSoumyajit Roy, Yilun Sun, Scott C Morgan, et al.
Practical Radiation Oncology|October 17, 2018
Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based GuidelineScott C Morgan, Karen Hoffman, D Andrew Loblaw, et al.
The Journal of Urology|February 15, 2019
Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based GuidelineScott C Morgan, Karen Hoffman, D Andrew Loblaw, et al.
Cancer|September 4, 2025
Association of patient and physician characteristics with androgen-deprivation-therapy intensification in patients with de novo hormone-sensitive metastatic prostate cancer: A population-based studyDavid-Dan Nguyen, Raj Satkunasivam, Khatereh Aminoltejari, et al.
JAMA Network Open|October 15, 2024
Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical TrialSoumyajit Roy, Shawn Malone, Kevin Wing, et al.
The Journal of Urology|July 26, 2024
Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of the TITAN TrialSoumyajit Roy, Yilun Sun, Kim N Chi, et al.
JNCI Cancer Spectrum|December 20, 2021
Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate CancerChristopher J D Wallis, Shawn Malone, Ilias Cagiannos, et al.
Cancers|July 2, 2021
Prognostic Association between Common Laboratory Tests and Overall Survival in Elderly Men with De Novo Metastatic Castration Sensitive Prostate Cancer: A Population-Based Study in CanadaChristopher J D Wallis, Bobby Shayegan, Scott C Morgan, et al.
Pageof 8